The use of publicly funded toplperisone, baclofen and tizanidine muscle relaxants medications in Hungary between 2015 and 2019
https://doi.org/10.56626/egis.v2i1.11110
Authors
View
Keywords
License
Copyright (c) 2023 Health Innovation Review
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Az Egészségügyi Innovációs Szemle folyóiratban megjelenő cikkek szabadon megoszthatók, másolhatók az anyagok bármilyen megjelenési formájában a "CC Attribution-NonCommercial-NoDerivatives 4.0" licenszben szereplő szabályok betartásával.
A cikkek változtatás nélkül terjeszthetők, és kereskedelmi felhasználásuk tilos.
How To Cite
Abstract
With the ageing of populations, the incidence and prevalence of disability increases. Disability is not just a health problem, it is a global social and economic problem. Within the disabled community, the physically disabled are the highest proportion. Treatment of muscle tone is fundamental importance. We examined the redemption, the funded of support and pay fee of the drugs baclofen, tolperisone and tizanidine between 2015 and 2019 in Hungary. The funded of support by the National Health Insurance Fund increased continuously during the examined period. This overall increase was mainly due to an increased the funded of support tizanidine. There was no noteworthy change in either the funded of support or pay fee for baclofen and tolperisone.